期刊
ALLERGY
卷 67, 期 8, 页码 976-997出版社
WILEY
DOI: 10.1111/j.1398-9995.2012.02865.x
关键词
asthma; children; consensus; guidelines; wheeze
资金
- Nestle
- MSD
- Deviblis (EBT)
- MRC Moulton Charitable Foundation
- Merck Inc
- Astra Zeneca
- GlaxoSmithKline
- AstraZeneca
- Novartis Research
- PREDICTA: European Commission [260895]
- Swiss National Science Foundation Research
- MeDALL: European Commission [261357]
- Christine Kuhne-Center for Allergy Research and Education Research
- Food Allergy and Anaphylaxis Network
- Food Allergy Initiative
- NIH
- National Peanut Board
- SHS
- Wallace Research Foundation
- Altus Pharmaceuticals
- Inspire Pharmaceuticals
- National Institutes of Health
- NIH [U01]
- AAAAI/GlaxoSmithKline
- Pharmaxis
- Grupo Uriach Pharma
- Turkish National Science Foundation
- Hacettepe University
- GSK
- Adamed
- SymbioPharm
- Airsonett
- Forest Pharmaceuticals
- Viro Pharma
- Novartis
- ALA, Pharmaceuticals
- National and regional grants for research in our group
- Novartis Pharma
- MEDA Pharma
- CBF LETI
- Allergopharma
- Inmunotek
- UK National Health Service
- Aerocrine
- Boehringer Ingelheim
- Merck
- Mundipharma
- Nycomed
- Pfizer
- Teva
- Ross
- Abbott
- Merck Sharp Dohme
- Genentech
- MedImmune
- Thermofisher
Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据